Search

Displaying results 1981 - 1990 of 10000 in total
  1. Drug

    P-113D

    go.drugbank.com/drugs/DB04987
    Experimental

    P-113D is a novel 12 amino-acid antimicrobial peptide drug derived from histatins, which are compounds found naturally in human saliva. … It is being pursued as a potential treatment for cystic fibrosis by Demegen, Inc.

    Synonyms: D-PEPTIDE OF THE SEQUENCE AKRHHGYKRKFH - NH2
  2. Drug

    Ty800

    go.drugbank.com/drugs/DB04989
    Investigational

    Ty800 is a vaccine designed to offer rapid, oral, single-dose protection against <i>Salmonella typhi</i>, the cause of typhoid fever. … The Ty800 vaccine was developed using genetic techniques to delete specific genes known to be essential to the virulence of <i>S. typhi</i>. It is being developed by AVANT Immunotherapeutics, Inc.

  3. Drug

    AT1022

    go.drugbank.com/drugs/DB04995
    Experimental

    AT1022 is a hydromorphone skin patch designed to provide rapid and sustained delivery of a potent opiate for the management of severe pain.

  4. Drug

    Adecatumumab

    go.drugbank.com/drugs/DB05006
    Investigational

    Adecatumumab is a recombinant human monoclonal antibody of the IgG1 subclass with a binding specificity to epithelial cell adhesion molecule (EpCAM). … EpCAM (CD326) is a cell surface protein that is frequently expressed at high level on most solid tumor types, including prostate, breast, colon, gastric, ovarian, pancreatic and lung cancer.

  5. Drug

    SGS-742

    go.drugbank.com/drugs/DB05010
    Investigational

    SGS-742 has been used in trials studying the treatment of Seizures and Metabolic Disease.

    Synonyms: (3-Aminopropyl)(n-butyl)phosphinic acid, 3-Aminopropyl-Butyl Phosphinic AcidCategories: Compounds used in a research, industrial, or household setting
  6. Drug

    XL999

    go.drugbank.com/drugs/DB05014
    Investigational

    XL999 is a new chemical entity that inhibits a spectrum of receptor tyrosine kinases (RTKs) with growth promoting and angiogenic properties, including FGFR 1/3, PDGFRα/β, VEGFR2/KDR, KIT, and FLT3. … XL999 induces a cell-cycle block by a mechanism distinct from those previously identified and exhibits broad antitumor activity in xenograft models.

  7. Drug

    Ataluren

    go.drugbank.com/drugs/DB05016
    ApprovedWithdrawn

    Ataluren is a novel, orally administered drug that targets nonsense mutations. … More specifically, ataluren is used in the small group of patients whose disease is caused by a specific genetic defect (called a ‘nonsense mutation’) in the dystrophin gene.

    Categories: Heterocyclic Compounds, 1-RingSynonyms: 3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid
  8. Drug

    LC16M8

    go.drugbank.com/drugs/DB05019
    Investigational

    LC16m8 is a next-generation, attenuated smallpox vaccine that is designed to have a better safety profile, yet be equally effective, compared to conventional smallpox vaccines.

  9. Drug

    Besifovir dipivoxil

    go.drugbank.com/drugs/DB05020
    Investigational

    Besifovir dipivoxil is a small-molecule orally available inhibitor of the HBV polymerase. The HBV polymerase is the enzyme that catalyzes the production of new RNA from the existing strand of RNA.

    Categories: Heterocyclic Compounds, 2-Ring
  10. Drug

    Lunacalcipol

    go.drugbank.com/drugs/DB05024
    Investigational

    CTA018 is a member of a new class of vitamin D analogues with a dual mechanism of action, called Vitamin D Signal Amplifiers. … This proprietary new drug is both a potent inhibitor of CYP24 (the enzyme responsible for the breakdown of vitamin D) and a potent activator of vitamin D signaling pathways.